Amani Therapeutics

About Amani Therapeutics

Amani Therapeutics is focused on removing barriers with innovative science to deliver effective treatments for people living with serious psychiatric illnesses. Their mission is to drive innovative science for safer and more effective psychiatric treatments, restoring hope and stability to enable fuller lives.

Products & Services

AM-01:A fixed-dose combination product including clozapine and a Phase 3-ready NCE, with potential to deliver clozapine's efficacy for schizophrenia while addressing severe neutropenia and reducing burdensome blood-monitoring requirements.

Specialties

Psychiatric treatments Neuropsychiatric disorders Schizophrenia treatment innovation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 25000000 MR: - FA: $25 million FAN: 25000000	D: 2026-03-23 FD: 2026-03-23	1 investors

Series A Latest

2026-03-23

$25.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Rob Swoboda

Chief Operating Officer

C

Carla Canuso

Chief Medical Officer

T

Tricia Cotter

Vice President, Clinical Operations

P

Praveen Kandi

Vice President, CMC

A

Alexander Vandell

Senior Director, Clinical Development

J

Jaclyn Scott

Director, Program and Alliance Management

View 4 more team members with Pro

Unlock Full Team Directory

Recent News